Bayer announced the start of a Phase III clinical development program “OCEANIC” to investigate the efficacy and safety of asundexian (BAY 2433334), an investigational...
Bristol Myers Squibb in collaboration with Janssen Pharmaceuticals, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen), announced results from the...
New results from a pre-specified, patient level, pooled analysis from the Phase III DAPA-HF and DELIVER trials demonstrated mortality benefit of FARXIGA® (dapagliflozin), compared...
Athos Therapeutics, Inc. is a late-stage preclinical biotech company using Artificial Intelligence (AI) to develop small molecule therapeutics for immune-mediated diseases and cancer. Athos...
Regen BioPharma, Inc. announced development of a novel immunotherapy for treatment of solid tumors. Current cellular approaches to kill cancer involve administration of a...
